Autologous conditioned serum (ACS) for intra-articular treatment in Osteoarthritis: Retrospective report of 28 cases

M Tassara, Alessandro De Ponti, Lorena Barzizza, M. Zambelli, C Parisi, Raffaella Milani, L Santoleri

Research output: Contribution to journalArticle

Abstract

Introduction: Autologous conditioned serum (ACS) is a novel blood product developed for intra-articular injection as a novel therapy for Osteoarthritis (OA). This study is a retrospective evaluation of 28 cases (25 Knee-OA and 3 hip-OA) treated with ACS between November 2013 and February 2016. Materials and methods: ACS was prepared according to standards in an accredited Cell Manipulation Lab, and applied by an expert clinician (2 ml injection once weekly over 4 weeks). At any injection visit (Timepoints 1–4), and after a follow-up of 1 (Timepoint 5) and 6 months (Timepoint 6), patients were asked to describe the intensity of their pain with the VAS (visual analog scale) psychometric scale, and the objective parameter ROM (Range Of Motion) was recorded in case of injection in the knee. Results: Pain (VAS) reduced in all cases since the first injection up to Timepoint 5. A significant improvement was observed in VAS between Timepoint 1 and 6 (primary objective), with a median VAS decrease of 60 mm (range 20–100, p <0.01). A significant difference was also recorded in ROM between Timepoint 1 and 6 (secondary objective), with a median increase of 25° (range 5–40, p <0.01). Ten out of 14 patients (71%) who were undergoing a chronic therapy to relieve pain were able to interrupt it. No serious adverse events were recorded. Conclusions: Treatment with ACS produced a rapid decline in pain, accompanied by a large improvement in ROM. These results suggest that ACS is a valid option for the treatment of OA. © 2018 Elsevier Ltd
Original languageEnglish
Pages (from-to)573-577
Number of pages5
JournalTransfusion and Apheresis Science
Volume57
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Osteoarthritis
Joints
Articular Range of Motion
Serum
Hip Osteoarthritis
Injections
Pain Measurement
Visual Analog Scale
Therapeutics
Pain
Intra-Articular Injections
Knee Osteoarthritis
Psychometrics
Knee

Cite this

Autologous conditioned serum (ACS) for intra-articular treatment in Osteoarthritis: Retrospective report of 28 cases. / Tassara, M; De Ponti, Alessandro; Barzizza, Lorena; Zambelli, M.; Parisi, C; Milani, Raffaella; Santoleri, L.

In: Transfusion and Apheresis Science, Vol. 57, No. 4, 2018, p. 573-577.

Research output: Contribution to journalArticle

Tassara, M ; De Ponti, Alessandro ; Barzizza, Lorena ; Zambelli, M. ; Parisi, C ; Milani, Raffaella ; Santoleri, L. / Autologous conditioned serum (ACS) for intra-articular treatment in Osteoarthritis: Retrospective report of 28 cases. In: Transfusion and Apheresis Science. 2018 ; Vol. 57, No. 4. pp. 573-577.
@article{35451e3d900e4850833bd205bc6fad84,
title = "Autologous conditioned serum (ACS) for intra-articular treatment in Osteoarthritis: Retrospective report of 28 cases",
abstract = "Introduction: Autologous conditioned serum (ACS) is a novel blood product developed for intra-articular injection as a novel therapy for Osteoarthritis (OA). This study is a retrospective evaluation of 28 cases (25 Knee-OA and 3 hip-OA) treated with ACS between November 2013 and February 2016. Materials and methods: ACS was prepared according to standards in an accredited Cell Manipulation Lab, and applied by an expert clinician (2 ml injection once weekly over 4 weeks). At any injection visit (Timepoints 1–4), and after a follow-up of 1 (Timepoint 5) and 6 months (Timepoint 6), patients were asked to describe the intensity of their pain with the VAS (visual analog scale) psychometric scale, and the objective parameter ROM (Range Of Motion) was recorded in case of injection in the knee. Results: Pain (VAS) reduced in all cases since the first injection up to Timepoint 5. A significant improvement was observed in VAS between Timepoint 1 and 6 (primary objective), with a median VAS decrease of 60 mm (range 20–100, p <0.01). A significant difference was also recorded in ROM between Timepoint 1 and 6 (secondary objective), with a median increase of 25° (range 5–40, p <0.01). Ten out of 14 patients (71{\%}) who were undergoing a chronic therapy to relieve pain were able to interrupt it. No serious adverse events were recorded. Conclusions: Treatment with ACS produced a rapid decline in pain, accompanied by a large improvement in ROM. These results suggest that ACS is a valid option for the treatment of OA. {\circledC} 2018 Elsevier Ltd",
author = "M Tassara and {De Ponti}, Alessandro and Lorena Barzizza and M. Zambelli and C Parisi and Raffaella Milani and L Santoleri",
year = "2018",
doi = "10.1016/j.transci.2018.07.021",
language = "English",
volume = "57",
pages = "573--577",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Autologous conditioned serum (ACS) for intra-articular treatment in Osteoarthritis: Retrospective report of 28 cases

AU - Tassara, M

AU - De Ponti, Alessandro

AU - Barzizza, Lorena

AU - Zambelli, M.

AU - Parisi, C

AU - Milani, Raffaella

AU - Santoleri, L

PY - 2018

Y1 - 2018

N2 - Introduction: Autologous conditioned serum (ACS) is a novel blood product developed for intra-articular injection as a novel therapy for Osteoarthritis (OA). This study is a retrospective evaluation of 28 cases (25 Knee-OA and 3 hip-OA) treated with ACS between November 2013 and February 2016. Materials and methods: ACS was prepared according to standards in an accredited Cell Manipulation Lab, and applied by an expert clinician (2 ml injection once weekly over 4 weeks). At any injection visit (Timepoints 1–4), and after a follow-up of 1 (Timepoint 5) and 6 months (Timepoint 6), patients were asked to describe the intensity of their pain with the VAS (visual analog scale) psychometric scale, and the objective parameter ROM (Range Of Motion) was recorded in case of injection in the knee. Results: Pain (VAS) reduced in all cases since the first injection up to Timepoint 5. A significant improvement was observed in VAS between Timepoint 1 and 6 (primary objective), with a median VAS decrease of 60 mm (range 20–100, p <0.01). A significant difference was also recorded in ROM between Timepoint 1 and 6 (secondary objective), with a median increase of 25° (range 5–40, p <0.01). Ten out of 14 patients (71%) who were undergoing a chronic therapy to relieve pain were able to interrupt it. No serious adverse events were recorded. Conclusions: Treatment with ACS produced a rapid decline in pain, accompanied by a large improvement in ROM. These results suggest that ACS is a valid option for the treatment of OA. © 2018 Elsevier Ltd

AB - Introduction: Autologous conditioned serum (ACS) is a novel blood product developed for intra-articular injection as a novel therapy for Osteoarthritis (OA). This study is a retrospective evaluation of 28 cases (25 Knee-OA and 3 hip-OA) treated with ACS between November 2013 and February 2016. Materials and methods: ACS was prepared according to standards in an accredited Cell Manipulation Lab, and applied by an expert clinician (2 ml injection once weekly over 4 weeks). At any injection visit (Timepoints 1–4), and after a follow-up of 1 (Timepoint 5) and 6 months (Timepoint 6), patients were asked to describe the intensity of their pain with the VAS (visual analog scale) psychometric scale, and the objective parameter ROM (Range Of Motion) was recorded in case of injection in the knee. Results: Pain (VAS) reduced in all cases since the first injection up to Timepoint 5. A significant improvement was observed in VAS between Timepoint 1 and 6 (primary objective), with a median VAS decrease of 60 mm (range 20–100, p <0.01). A significant difference was also recorded in ROM between Timepoint 1 and 6 (secondary objective), with a median increase of 25° (range 5–40, p <0.01). Ten out of 14 patients (71%) who were undergoing a chronic therapy to relieve pain were able to interrupt it. No serious adverse events were recorded. Conclusions: Treatment with ACS produced a rapid decline in pain, accompanied by a large improvement in ROM. These results suggest that ACS is a valid option for the treatment of OA. © 2018 Elsevier Ltd

U2 - 10.1016/j.transci.2018.07.021

DO - 10.1016/j.transci.2018.07.021

M3 - Article

VL - 57

SP - 573

EP - 577

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 4

ER -